EDGE THERAPEUTICS, INC. Common Stock, par value $0.00033 per share UNDERWRITING AGREEMENTUnderwriting Agreement • September 21st, 2015 • Edge Therapeutics, Inc. • Pharmaceutical preparations • New York
SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • September 21st, 2015 • Edge Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
This Second Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of September 21, 2015 by and between Edge Therapeutics, Inc., a Delaware corporation (the “Company”), and R. Loch Macdonald (“Executive”). This Agreement shall become effective as of the closing of the Company’s initial public offering (the “Effective Date”).
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. AMENDMENT NO. 1 TO THE LICENSE AGREEMENTThe License Agreement • September 21st, 2015 • Edge Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT (the “Amendment No. 1”), effective as of September 21, 2015 to the October 20, 2010 License Agreement (the “Agreement”) by and between Evonik Corporation (assignee of this Agreement by SurModics Pharmaceuticals, Inc.), an Alabama Corporation, with a principal place of business at 299 Jefferson Road, Parsippany, New Jersey 07054 and a facility at 750 Lakeshore Parkway, Birmingham, Alabama 35211 (“formerly “Evonik Degussa Corporation” and hereinafter “Evonik”) and Edge Therapeutics, Inc., a Delaware corporation having a place of business at 200 Connell Drive, Suite 1600, Berkeley Heights, New Jersey 07922 (“Edge”) is made by and between Evonik and Edge.
